Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VTAK vs TVGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TVGN Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–1 Matrix Metrics)

TVGN Overall Winner 6-Pillar Tally: VTAK 2 – 2 TVGN (2 Tie) Matrix Metrics: VTAK 1 – 6 TVGN

As of Nov 16, 2026, Tevogen Bio Holdings Inc. (TVGN) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). VTAK carries a Unified Composite Score of 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin), whereas TVGN carries 60.3/100 (BUY) at $6.22 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: TVGN earns the overall head-to-head edge with a stronger Unified Composite Score (60.3/100 BUY vs. VTAK 58.1/100 HOLD) and 1.60β · 60% Vol risk profile, whereas VTAK leads top-line expansion (+380.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile TVGN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTAK vs TVGN
VTAK NYSE American
Catheter Precision, Inc.
Surgical & Medical Instruments & Apparatus
$0.15
-0.66% 1D
Market Cap $548,639
TTM Revenue $1.9M
Forward P/E N/M
Beta / 30D Vol 0.19β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 72.0 Fund 70.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -53.4%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $0.16 · SMA50: $0.21
TVGN NASDAQ Head-to-Head Winner
Tevogen Bio Holdings Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.22
+3.67% 1D
Market Cap $406.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.60β · 60% Vol
Unified Composite Score
60.3 / 100 BUY
Tech 97.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.2 · SMA20: $6.05 · SMA50: $6.70

6-Pillar Scorecard Institutional Category Breakdown (VTAK 2 – 2 TVGN)

Columns: Metric · VTAK · TVGN
1. Valuation Multiples VTAK
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.3x N/M
2. Growth & Scale VTAK
Revenue Growth (YoY) +380.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.9M N/A
Market Cap $548,639 $406.6M
3. Profitability & Quality TVGN
Gross Margin 47.7% N/A
Operating Margin -388.1% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -111.3% 0.0%
4. Balance Sheet & Cash Flow TVGN
Cash Generation (TTM) -$10M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.87 Book/Sh · -111.3% ROE 0.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTAK (1) vs TVGN (6)
Institutional Metric VTAK TVGN Criterion Row Edge
Market Capitalization
Scale
$548,639 $406.6M Larger Scale TVGN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+380.7% +0.0% Higher Growth VTAK
Operating Margin (TTM)
Profitability
-388.1% 0.0% Higher Margin TVGN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-111.3% 0.0% Higher ROE TVGN
52-Week Range Position
Momentum
1% ($0–$3) 51% ($0–$12) Stronger Trend TVGN
Beta / 30D Volatility
Risk Regime
0.19β · 76% Vol 1.60β · 60% Vol Lower Realized Risk TVGN
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 60.3 / 100 (BUY) Higher Composite TVGN
Trailing 12M Revenue (USD)
Operating Scale
$1.9M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
47.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$10M EBITDA ($4.87 Book/Sh · -111.3% ROE) N/A (0.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TVGN +21.2 pp
VTAK: -23.85% · TVGN: -2.65%
3M Horizon TVGN +101.86 pp
VTAK: -80.89% · TVGN: +20.97%
6M Horizon TVGN +139.74 pp
VTAK: -83.94% · TVGN: +55.8%
1Y Horizon TVGN +1491.31 pp
VTAK: -93.46% · TVGN: +1397.85%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VTAK vs TVGN. Trailing 12-month operating profitability (VTAK -388.1% vs TVGN 0.0%) and valuation multiples (VTAK N/M vs TVGN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VTAK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.9M
Gross Margin47.7%
Op. Margin-388.1%
ROE / Fwd P/E-111.3% · N/M
TVGN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E0.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TVGN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TVGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTAK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $548,639 market capitalization and -388.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TVGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $406.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VTAK vs TVGN Key Questions & Quantitative Answers

As of Nov 16, 2026, Tevogen Bio Holdings Inc. (TVGN) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). VTAK carries a Unified Composite Score of 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin), whereas TVGN carries 60.3/100 (BUY) at $6.22 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: TVGN earns the overall head-to-head edge with a stronger Unified Composite Score (60.3/100 BUY vs. VTAK 58.1/100 HOLD) and 1.60β · 60% Vol risk profile, whereas VTAK leads top-line expansion (+380.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile TVGN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VTAK leads the Growth & Scale pillar: VTAK posts +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin), compared with TVGN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VTAK generates $1.9M in USD-normalized revenue versus N/A for TVGN. In operating R&D and SG&A reinvestment, VTAK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TVGN.

VTAK screens cheaper on headline valuation multiples. VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin), whereas TVGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTAK (-111.3% ROE) versus TVGN (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk). By comparison, TVGN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.60β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.